Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain

Verrica Pharmaceuticals ((VRCA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Verrica Pharmaceuticals’ latest earnings call painted a picture of strong operational progress offset by familiar financial strain. Management highlighted accelerating momentum for YCANTH and impressive Phase II data for VP-315, while acknowledging continued net losses, rising expenses and a cash runway that likely forces new funding within the next year.

Revenue Growth

Verrica reported Q1 2026 revenue of $5.0 million, anchored by $4.3 million in U.S. YCANTH product sales. That YCANTH figure represents a 25.4% year-over-year increase, signaling that the commercial ramp is gaining traction even as the overall revenue base remains modest for a commercial-stage biotech.

Strong Unit Dispensation Momentum

YCANTH’s underlying demand trends looked even stronger than revenue alone, with 15,302 U.S. applicator units dispensed in Q1, up 51.3% from a year earlier. Sequential momentum also remained healthy, as revenue rose 15.3% and units 12.1% versus Q4 2025, with March marking a record month and April tracking even higher.

International Commercial Milestone — Japan Launch

International expansion took a key step forward as partner Torii, now under Shionogi, launched YCANTH in Japan in February 2026. Supply shipments to Torii not only open a new revenue stream but will also begin to offset Verrica’s share of common warts trial costs, with Torii funding the first $40 million of the program.

Progress in Common Warts Phase III Program

Verrica’s global Phase III program for common warts is underway, with the first patient dosed in January and the COVE-2 trial already past 50% of targeted enrollment. The company has also started long-term follow-up in COVE-4 and plans to initiate the COVE-3 study by mid-2026, underscoring the strategic importance of this broader indication.

VP-315 Phase II Clinical Strength

Pipeline news was highlighted by VP-315 for basal cell carcinoma, which delivered a 97% objective response rate and an average 86% tumor size reduction in Phase II. More than half of treated lesions achieved complete histologic resolution, and Verrica is now preparing for Phase III while conducting market research to define the commercial opportunity.

Regulatory and EU Pathway Progress

Regulatory momentum extended to Europe, where the EMA’s CHMP provided positive feedback supporting a YCANTH marketing application for molluscum. Crucially, no additional Phase III trials are required, allowing Verrica to move toward an EU submission and explore potential commercialization partnerships to leverage the asset overseas.

Commercial Infrastructure and Adoption Enhancements

To support adoption, Verrica launched YCANTH Rx, a hub and non-dispensing pharmacy solution designed to streamline benefit checks and fulfillment for prescribers. The company also installed a new Chief Commercial Officer and is re-optimizing its field force to about 50 representatives, expected to cover roughly 85% of its target addressable market, with more than 100,000 applicators dispensed since launch.

Operating Loss and Cash Runway

Despite commercial progress, the income statement remains in the red, with a GAAP net loss of $9.7 million and non-GAAP loss of $8.8 million in Q1 2026, roughly in line with last year. Cash stood at $20.6 million on March 31, which management believes will fund operations into Q1 2027, effectively signaling a likely financing event within about 12 months.

Rising Operational Spend

Operating expenses continue to climb as Verrica invests in its pipeline and launch infrastructure, with R&D reaching $3.9 million in Q1, up $1.5 million excluding stock-based compensation and driven largely by common warts studies. SG&A rose to $10 million, an increase of $1.3 million excluding stock-based comp, reflecting the expanded commercial footprint and support functions.

Gross-to-Net and Access Dynamics

YCANTH’s gross product margin remained robust at 87.3%, only slightly down from 87.6% a year earlier, but net revenue continues to be shaped by gross-to-net adjustments. Returns, discounts, rebates and co-pay assistance weigh on reported sales, with co-pay costs spiking early each year as patient deductibles reset, causing seasonal variability in net results.

Market Adoption Challenges — Pediatric & PBM Access

Management emphasized that the market is still shifting from a traditional “watch-and-wait” mindset toward active treatment of molluscum, especially in children. Verrica sees room to expand beyond dermatologists into pediatricians and physician extenders and still faces work to improve pull-through in pediatric accounts at pharmacy benefit managers and to close geographic access gaps.

No Formal 2026 Guidance Provided

Although April demand trends exceeded March’s record levels, Verrica chose not to issue formal 2026 revenue guidance, leaving investors to model near-term performance with limited visibility. The company indicated that more specific financial guidance is likely later in 2026, potentially around the third or fourth quarter as data and adoption trends mature.

Reliance on Partner-Funded Trial Structure

The common warts Phase III program is under a 50/50 cost-sharing deal with Torii, with Torii covering the first $40 million, or roughly 90% of the current trial budget. Verrica expects to repay its share over time through offsets to future Japan-related payments, underscoring how its development plans hinge on partner arrangements and future regional sales.

Forward-Looking Guidance and Milestones

Looking ahead, Verrica is steering investors toward operational markers rather than formal revenue targets, spotlighting unit growth, field force optimization and international ramp as near-term barometers. On the development side, advancing the COVE Phase III common warts program, transitioning VP-315 into Phase III and progressing the EU filing for YCANTH are key catalysts, alongside managing expenses and extending the cash runway.

Verrica’s earnings call showcased a company with genuine commercial and clinical momentum but still in the classic crossover zone between development-stage and sustainable profitability. For investors, the story now hinges on whether YCANTH’s adoption curve and the expanding pipeline can outpace rising costs and an impending funding need, turning today’s promise into durable earnings power.